747 related articles for article (PubMed ID: 21300764)
1. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.
Burnette BC; Liang H; Lee Y; Chlewicki L; Khodarev NN; Weichselbaum RR; Fu YX; Auh SL
Cancer Res; 2011 Apr; 71(7):2488-96. PubMed ID: 21300764
[TBL] [Abstract][Full Text] [Related]
2. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation.
Chen J; Cao Y; Markelc B; Kaeppler J; Vermeer JA; Muschel RJ
J Clin Invest; 2019 Oct; 129(10):4224-4238. PubMed ID: 31483286
[TBL] [Abstract][Full Text] [Related]
3. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
[TBL] [Abstract][Full Text] [Related]
4. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells.
Lim JY; Gerber SA; Murphy SP; Lord EM
Cancer Immunol Immunother; 2014 Mar; 63(3):259-71. PubMed ID: 24357146
[TBL] [Abstract][Full Text] [Related]
5. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
[TBL] [Abstract][Full Text] [Related]
6. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.
Fuertes MB; Kacha AK; Kline J; Woo SR; Kranz DM; Murphy KM; Gajewski TF
J Exp Med; 2011 Sep; 208(10):2005-16. PubMed ID: 21930765
[TBL] [Abstract][Full Text] [Related]
7. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
[TBL] [Abstract][Full Text] [Related]
8. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
9. Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity.
Zhang F; Manna S; Pop LM; Chen ZJ; Fu YX; Hannan R
Semin Radiat Oncol; 2020 Apr; 30(2):129-138. PubMed ID: 32381292
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.
Simmons DP; Canaday DH; Liu Y; Li Q; Huang A; Boom WH; Harding CV
J Immunol; 2010 Aug; 185(4):2405-15. PubMed ID: 20660347
[TBL] [Abstract][Full Text] [Related]
11. Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment.
Gangaplara A; Martens C; Dahlstrom E; Metidji A; Gokhale AS; Glass DD; Lopez-Ocasio M; Baur R; Kanakabandi K; Porcella SF; Shevach EM
PLoS Pathog; 2018 Apr; 14(4):e1006985. PubMed ID: 29672594
[TBL] [Abstract][Full Text] [Related]
12. Myd88 Initiates Early Innate Immune Responses and Promotes CD4 T Cells during Coronavirus Encephalomyelitis.
Butchi N; Kapil P; Puntambekar S; Stohlman SA; Hinton DR; Bergmann CC
J Virol; 2015 Sep; 89(18):9299-312. PubMed ID: 26136579
[TBL] [Abstract][Full Text] [Related]
13. Type I interferon is selectively required by dendritic cells for immune rejection of tumors.
Diamond MS; Kinder M; Matsushita H; Mashayekhi M; Dunn GP; Archambault JM; Lee H; Arthur CD; White JM; Kalinke U; Murphy KM; Schreiber RD
J Exp Med; 2011 Sep; 208(10):1989-2003. PubMed ID: 21930769
[TBL] [Abstract][Full Text] [Related]
14. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity.
Liang Y; Hannan R; Fu YX
Clin Cancer Res; 2021 Jul; 27(14):3818-3824. PubMed ID: 33692027
[TBL] [Abstract][Full Text] [Related]
15. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor.
Kono DH; Baccala R; Theofilopoulos AN
Autoimmunity; 2003 Dec; 36(8):503-10. PubMed ID: 14984027
[TBL] [Abstract][Full Text] [Related]
17. Type I IFN-induced, NKT cell-mediated negative control of CD8 T cell priming by dendritic cells.
Bochtler P; Kröger A; Schirmbeck R; Reimann J
J Immunol; 2008 Aug; 181(3):1633-43. PubMed ID: 18641299
[TBL] [Abstract][Full Text] [Related]
18. IRF-7 is the master regulator of type-I interferon-dependent immune responses.
Honda K; Yanai H; Negishi H; Asagiri M; Sato M; Mizutani T; Shimada N; Ohba Y; Takaoka A; Yoshida N; Taniguchi T
Nature; 2005 Apr; 434(7034):772-7. PubMed ID: 15800576
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.
Van der Jeught K; Joe PT; Bialkowski L; Heirman C; Daszkiewicz L; Liechtenstein T; Escors D; Thielemans K; Breckpot K
Oncotarget; 2014 Oct; 5(20):10100-13. PubMed ID: 25338019
[TBL] [Abstract][Full Text] [Related]
20. Autocrine Type I IFN Signaling in Dendritic Cells Stimulated with Fungal β-Glucans or Lipopolysaccharide Promotes CD8 T Cell Activation.
Hassanzadeh-Kiabi N; Yáñez A; Dang I; Martins GA; Underhill DM; Goodridge HS
J Immunol; 2017 Jan; 198(1):375-382. PubMed ID: 27872213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
